Lemtrada and Mean cell haemoglobin concentration increased - a phase IV clinical study of FDA data

Summary:

Mean cell haemoglobin concentration increased is reported as a side effect among people who take Lemtrada (alemtuzumab), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Gravol, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Mean cell haemoglobin concentration increased when taking Lemtrada. It is created by eHealthMe based on reports of 8,297 people who have side effects when taking Lemtrada from the FDA, and is updated regularly.

What is Lemtrada?

Lemtrada has active ingredients of alemtuzumab. eHealthMe is studying from 8,317 Lemtrada users. Check the latest studies of Lemtrada.

What is Mean cell haemoglobin concentration increased?

Mean cell haemoglobin concentration increased (more concentration of haemoglobin in a given volume of packed red blood cells) is found to be associated with 130 drugs and 241 conditions by eHealthMe. Check the latest studies of Mean cell haemoglobin concentration increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

8,297 people reported to have side effects when taking Lemtrada.
Among them, 21 people (0.25%) have Mean cell haemoglobin concentration increased.

Could Lemtrada cause Mean cell haemoglobin concentration increased?

Among these 21 people:

How long have people been on Lemtrada when they have Mean cell haemoglobin concentration increased? *

What is the gender of people who have Mean cell haemoglobin concentration increased when taking Lemtrada? *

female: 95.24 %
male: 4.76 %

What is the age of people who have Mean cell haemoglobin concentration increased when taking Lemtrada? *

What are other drugs people take besides Lemtrada? *

What are other side effects people have besides Mean cell haemoglobin concentration increased? *

Lymphocyte Count Decreased: 21 people, 100.00%
Fatigue (feeling of tiredness): 21 people, 100.00%
Nausea (feeling of having an urge to vomit): 21 people, 100.00%
Skin Blushing/flushing (a sudden reddening of the face, neck): 20 people, 95.24%
White Blood Cells Urine Positive: 20 people, 95.24%
Malaise (a feeling of general discomfort or uneasiness): 20 people, 95.24%
High Blood Pressure: 20 people, 95.24%
Headache (pain in head): 20 people, 95.24%
Drug Ineffective: 20 people, 95.24%
Culture Urine Positive: 20 people, 95.24%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 20 people, 95.24%
Joint Pain: 19 people, 90.48%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 18 people, 85.71%
Seasonal Allergy (allergic condition due to certain season): 1 person, 4.76%
Neuralgia (pain in one or more nerves): 1 person, 4.76%
Depression: 1 person, 4.76%
Birth Control: 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Lemtrada and have Mean cell haemoglobin concentration increased?

- Check whether Mean cell haemoglobin concentration increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lemtrada:

Lemtrada (8,317 reports)

Mean cell haemoglobin concentration increased treatments and more:

Mean cell haemoglobin concentration increased (775 reports)

How severe was Mean cell haemoglobin concentration increased and when was it recovered:

Mean cell haemoglobin concentration increased in Lemtrada

Expand to all the drugs that have ingredients of alemtuzumab:

Mean cell haemoglobin concentration increased and drugs with ingredients of alemtuzumab

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lemtrada:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mean cell haemoglobin concentration increased:

Mean cell haemoglobin concentration increased (130 drugs)

Browse all the conditions that are associated with Mean cell haemoglobin concentration increased:

Mean cell haemoglobin concentration increased (241 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alemtuzumab (the active ingredients of Lemtrada) and Lemtrada (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.